Your browser doesn't support javascript.
loading
Thrombus Migration and Fragmentation After Intravenous Alteplase Treatment: The INTERRSeCT Study.
Ohara, Tomoyuki; Menon, Bijoy K; Al-Ajlan, Fahad S; Horn, MacKenzie; Najm, Mohamed; Al-Sultan, Abdulaziz; Puig, Josep; Dowlatshahi, Dar; Calleja Sanz, Ana I; Sohn, Sung-Il; Ahn, Seong H; Poppe, Alexandre Y; Mikulik, Robert; Asdaghi, Negar; Field, Thalia S; Jin, Albert; Asil, Talip; Boulanger, Jean-Martin; Letteri, Federica; Dey, Sadanand; Evans, James W; Goyal, Mayank; Hill, Michael D; Almekhlafi, Mohammed; Demchuk, Andrew M.
Affiliation
  • Ohara T; Calgary Stroke Program, Hotchkiss Brain Institute, Departments of Clinical Neurosciences and Radiology, Cumming School of Medicine, University of Calgary, Canada (T.O., B.K.M., M.H., M.N., A.A.-S., M.G., M.D.H., M.A., A.M.D.).
  • Menon BK; Department of Neurology, Kyoto Prefectural University of Medicine, Kyoto, Japan (T.O.).
  • Al-Ajlan FS; Calgary Stroke Program, Hotchkiss Brain Institute, Departments of Clinical Neurosciences and Radiology, Cumming School of Medicine, University of Calgary, Canada (T.O., B.K.M., M.H., M.N., A.A.-S., M.G., M.D.H., M.A., A.M.D.).
  • Horn M; King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia (F.S.A.-A.).
  • Najm M; Calgary Stroke Program, Hotchkiss Brain Institute, Departments of Clinical Neurosciences and Radiology, Cumming School of Medicine, University of Calgary, Canada (T.O., B.K.M., M.H., M.N., A.A.-S., M.G., M.D.H., M.A., A.M.D.).
  • Al-Sultan A; Calgary Stroke Program, Hotchkiss Brain Institute, Departments of Clinical Neurosciences and Radiology, Cumming School of Medicine, University of Calgary, Canada (T.O., B.K.M., M.H., M.N., A.A.-S., M.G., M.D.H., M.A., A.M.D.).
  • Puig J; Calgary Stroke Program, Hotchkiss Brain Institute, Departments of Clinical Neurosciences and Radiology, Cumming School of Medicine, University of Calgary, Canada (T.O., B.K.M., M.H., M.N., A.A.-S., M.G., M.D.H., M.A., A.M.D.).
  • Dowlatshahi D; IDI-IDIBGI, Dr Josep Trueta University Hospital, Girona, Spain (J.P.).
  • Calleja Sanz AI; Department of Medicine, University of Ottawa and Ottawa Hospital Research Institute, Canada (D.D.).
  • Sohn SI; Department of Neurology, Universitary Clinical Hospital of Valladolid, Spain (A.I.C.-S.).
  • Ahn SH; Department of Neurology, Keimyung University, Daegu, Republic of Korea (S.-I.S.).
  • Poppe AY; Gwangju Institute of Science and Technology, Republic of Korea (S.H.A.).
  • Mikulik R; Department of Neurosciences, University of Montreal, Canada (A.Y.P.).
  • Asdaghi N; International Clinical Research Center, Department of Neurology, St Anne's University Hospital, Masaryk University, Brno, Czech Republic (R.M.).
  • Field TS; University of Miami, FL (N.A.).
  • Jin A; Division of Neurology, University of British Columbia, Vancouver, British Columbia, Canada (T.S.F.).
  • Asil T; Department of Medicine (Neurology), Queen's University, Kingston, Ontario, Canada (A.J.).
  • Boulanger JM; Bezmialem Vakif Univesitesi Noroloji, Istanbul, Turkey (T.A.).
  • Letteri F; Charles LeMoyne Hospital, Greenfield Park, QC, Canada (J.-M.B.).
  • Dey S; Istituto Don Calabria, IRCCS Sacro Cuore Hospital, Negrar, Italy (F.L.).
  • Evans JW; AMRI, Mukundapur, Kolkata, India (S.D.).
  • Goyal M; Gosford Hospital, Gosford, NSW, Australia (J.W.E.).
  • Hill MD; Calgary Stroke Program, Hotchkiss Brain Institute, Departments of Clinical Neurosciences and Radiology, Cumming School of Medicine, University of Calgary, Canada (T.O., B.K.M., M.H., M.N., A.A.-S., M.G., M.D.H., M.A., A.M.D.).
  • Almekhlafi M; Calgary Stroke Program, Hotchkiss Brain Institute, Departments of Clinical Neurosciences and Radiology, Cumming School of Medicine, University of Calgary, Canada (T.O., B.K.M., M.H., M.N., A.A.-S., M.G., M.D.H., M.A., A.M.D.).
  • Demchuk AM; Calgary Stroke Program, Hotchkiss Brain Institute, Departments of Clinical Neurosciences and Radiology, Cumming School of Medicine, University of Calgary, Canada (T.O., B.K.M., M.H., M.N., A.A.-S., M.G., M.D.H., M.A., A.M.D.).
Stroke ; 52(1): 203-212, 2021 01.
Article in En | MEDLINE | ID: mdl-33317416
BACKGROUND AND PURPOSE: There is interest in what happens over time to the thrombus after intravenous alteplase. We study the effect of alteplase on thrombus structure and its impact on clinical outcome in patients with acute stroke. METHODS: Intravenous alteplase treated stroke patients with intracranial internal carotid artery or middle cerebral artery occlusion identified on baseline computed tomography angiography and with follow-up vascular imaging (computed tomography angiography or first run of angiography before endovascular therapy) were enrolled from INTERRSeCT study (Identifying New Approaches to Optimize Thrombus Characterization for Predicting Early Recanalization and Reperfusion With IV Alteplase and Other Treatments Using Serial CT Angiography). Thrombus movement after intravenous alteplase was classified into complete recanalization, thrombus migration, thrombus fragmentation, and no change. Thrombus migration was diagnosed when occlusion site moved distally and graded according to degrees of thrombus movement (grade 0-3). Thrombus fragmentation was diagnosed when a new distal occlusion in addition to the primary occlusion was identified on follow-up imaging. The association between thrombus movement and clinical outcome was also evaluated. RESULTS: Among 427 patients in this study, thrombus movement was seen in 54% with a median time of 123 minutes from alteplase administration to follow-up imaging, and sub-classified as marked (thrombus migration grade 2-3 + complete recanalization; 27%) and mild to moderate thrombus movement (thrombus fragmentation + thrombus migration grade 0-1; 27%). In patients with proximal M1/internal carotid artery occlusion, marked thrombus movement was associated with a higher rate of good outcome (90-day modified Rankin Scale, 0-2) compared with mild to moderate movement (52% versus 27%; adjusted odds ratio, 5.64 [95% CI, 1.72-20.10]). No difference was seen in outcomes between mild to moderate thrombus movement and no change. In M1 distal/M2 occlusion, marked thrombus movement was associated with improved 90-day good outcome compared with no change (70% versus 56%; adjusted odds ratio, 2.54 [95% CI, 1.21-5.51]). CONCLUSIONS: Early thrombus movement is common after intravenous alteplase. Marked thrombus migration leads to good clinical outcomes. Thrombus dynamics over time should be further evaluated in clinical trials of acute reperfusion therapy.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tissue Plasminogen Activator / Stroke / Intracranial Thrombosis / Fibrinolytic Agents Type of study: Prognostic_studies Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Stroke Year: 2021 Document type: Article Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tissue Plasminogen Activator / Stroke / Intracranial Thrombosis / Fibrinolytic Agents Type of study: Prognostic_studies Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Stroke Year: 2021 Document type: Article Country of publication: